复合消肿疗法在有症状的慢性髂股静脉梗阻伴静脉淋巴水肿患者中的有益作用
本研究分析192条肢体(166例患者)的前瞻性数据,评估复合消肿疗法(CDT)在慢性髂股静脉梗阻(CIVO)所致静脉淋巴水肿中的疗效。方案为CEAP C3期先行CDT,更晚期(C4-C6)先支架再CDT。结果显示CDT后生活质量、疼痛及肿胀评分改善,C3组仅12%需支架,C4-C6组支架通畅率良好。
要点
- CEAP C3期患者CDT后VCSS、VAS疼痛及CIVIQ-20评分改善,仅12%需支架。
- CEAP C4-C6期患者支架后仍有症状者CDT可进一步改善症状。
- C4-C6组36个月一期、一期辅助及二期通畅率分别为92%、100%、100%。
核心结论
- 对于CEAP C3期由CIVO引起的静脉淋巴水肿患者,CDT应作为一线治疗的一部分。
- 支架应保留给尽管使用CDT但仍存在生活质量受损症状的患者。
- CDT有助于缓解CEAP C4-C6期患者支架后持续或残留水肿的症状。
- 需要进一步研究。
研究设计与样本
- 分析2017年至2022年间前瞻性收集的192条肢体(166例患者)数据,这些肢体因淋巴显像确定的静脉淋巴水肿导致生活质量受损症状而接受CIVO治疗。
- 评估指标包括CEAP临床分级、静脉临床严重程度评分(VCSS)、肿胀分级(GOS)、视觉模拟量表(VAS)疼痛评分、生活质量(CIVIQ-20)、CIVO支架植入及CDT和支架相关结局。
- CDT或支架后CDT的结局在CDT完成后6周及3、6、12个月评估。
- 使用配对和非配对t检验、χ2检验及方差分析比较临床变量,Kaplan-Meier分析评估支架通畅率,log-rank检验区分曲线。
主要发现
- C3组74条肢体,CDT后6周及3、6、12个月VCSS和VAS疼痛评分改善(均P < .0001),GOS在6个月(P < .0001)和12个月(P = .0005)改善,CIVIQ-20评分从63改善至38(P = .009)。
- C3组9条肢体(12%)在CDT后需要支架植入。
- C4-C6组118条肢体中,75条(64%)仅接受支架,43条(36%)因持续生活质量受损症状接受支架后CDT。
- C4-C6组支架后CDT的43条肢体,CDT后6周及3、6、12个月VCSS、GOS和VAS疼痛评分改善(均P < .0001),CIVIQ-20评分从61改善至34(P < .0001)。
- C4-C6组36个月一期、一期辅助和二期通畅率分别为92%、100%和100%。
关键数值与推荐
- CEAP C3期患者:CDT后VCSS和VAS疼痛评分在6周及3、6、12个月均P < .0001改善。
- CEAP C3期患者:GOS在6个月(P < .0001)和12个月(P = .0005)改善。
- CEAP C3期患者:CIVIQ-20评分从63改善至38(P = .009)。
- CEAP C4-C6期支架后CDT患者:CIVIQ-20评分从61改善至34(P < .0001)。
- CEAP C4-C6期患者:36个月一期通畅率92%,一期辅助通畅率100%,二期通畅率100%。
临床怎么用
- 对于CEAP C3期由CIVO引起的静脉淋巴水肿患者,CDT应作为一线治疗的一部分。
- 支架应保留给尽管使用CDT但仍存在生活质量受损症状的患者。
- 对于CEAP C4-C6期患者,支架后持续或残留水肿者,CDT有助于缓解症状。
局限性
- 需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Phlebolymphedema has been noted to be one of the most common causes of lymphedema in the lower extremity in western societies. Although complex decongestive therapy (CDT) represents the mainstay of lymphedema treatment, its role for phlebolymphedema arising from chronic iliofemoral venous obstruction (CIVO) merits further exploration. We evaluated this through the use of a protocol of CDT first for limbs with CEAP (clinical, etiologic, anatomic, pathophysiologic) clinical C3 disease and stent correction of obstruction before CDT for those with more advanced disease (CEAP C4-C6). In the present study, we analyzed the outcomes after the use of such a protocol. METHODS: We analyzed prospectively collected data for 192 limbs (166 patients) that underwent treatment of quality-of-life (QoL) impairing symptoms from CIVO due to lymphoscintigraphically determined phlebolymphedema between 2017 and 2022. The characteristics evaluated included CEAP clinical class, venous clinical severity score (VCSS), grade of swelling (GOS), visual analog scale (VAS) pain score, QoL (CIVIQ-20 [20-item chronic venous disease quality of life questionnaire]), stenting for CIVO, and outcomes related to CDT and stenting. For the limbs undergoing CDT or stenting followed by CDT, the outcomes were evaluated at 6 weeks and 3, 6, and 12 months after completion of CDT. Paired and unpaired t tests, χ2 tests, and analysis of variance were used for comparisons of clinical variables. Kaplan-Meier analysis was used to evaluate stent patency, with the log-rank test used to discriminate between different curves. RESULTS: Of the 192 limbs (166 patients) in the entire cohort, 74 were in the C3 group and 118 were in the C4-C6 group. The median patient age was 63 years; 57 were men and 109 were women. In the C3 group, after CDT, improvement had occurred in the VCSS and VAS pain score at 6 weeks (P < .0001) and at 3 (P < .0001), 6 (P < .0001), and 12 (P < .0001) months. Improvement in the GOS was noted at 6 (P < .0001) and 12 (P = .0005) months. The CIVIQ-20 score improved from 63 to 38 (P = .009). Nine limbs (12%) in the C3 group required stenting after CDT. In the C4-C6 group, of the 118 limbs, 75 (64%) underwent stenting only and 43 (36%) underwent stenting followed by CDT for persistent QoL impairing symptoms. For this latter group, after CDT, improvement occurred in the VCSS, GOS, and VAS pain score at 6 weeks (P < .0001) and 3 (P < .0001), 6 (P < .0001), and 12 (P < .0001) months. The CIVIQ-20 score improved from 61 to 34 (P < .0001). The primary, primary assisted, and secondary patency in the C4-C6 group at 36 months was 92%, 100%, and 100%, respectively. CONCLUSIONS: For CEAP C3 patients with phlebolymphedema due to CIVO, CDT should be a part of the first line of treatment. Stenting should be reserved for those with QoL impairing symptoms despite the use of CDT. Additionally, CDT helps provide symptom relief for patients with more advanced CEAP C4-C6 disease with persistent or residual edema after stenting. Further study is warranted.
引用
- Jayaraj A, Thaggard D. The beneficial role of complex decongestive therapy in patients with symptomatic chronic iliofemoral venous obstruction with phlebolymphedema. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37714459. doi:10.1016/j.jvsv.2023.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。